A vaccine for Alzheimer’s disease appears to improve learning and memory deficits in mice. Findings from Brig-ham and Women’s Hospital and Harvard University have shown promise for a potentially safer and more effective Alzheimer’s vaccine in humans.
One theory is that amyloid-beta plaques (clumps of protein) build up between nerve cells in the brain and contribute to cognitive and behavioral deficits. Scientists have developed a vaccine using a special type of amyloid-beta substance that can trigger the immune system to produce antibodies that reduce the buildup of plaques in the brains of mice. canadian antibiotics
The vaccine, given by nose drops, targets only the region of the amyloid-beta protein involved in generating antibodies against amyloid-beta, and it avoids the immune response in mice that had been thought to cause brain inflammation, observed with an earlier vaccine in humans. The new vaccine still produced antibodies that cleared the brain of amyloid deposits.